Tebideutorexant

Tebideutorexant
Clinical data
Other namesJNJ-61393215; JNJ-3215
Routes of
administration		Oral
Drug classOrexin receptor antagonist
Pharmacokinetic data
Elimination half-life14–25 hours[1]
Identifiers
IUPAC name
  • [(1S,4R,6R)-3,3-dideuterio-6-[5-(trifluoromethyl)pyridin-2-yl]oxy-2-azabicyclo[2.2.1]heptan-2-yl]-(3-fluoro-2-pyrimidin-2-ylphenyl)methanone
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC23H18F4N4O2
Molar mass458.417 g·mol−1
3D model (JSmol)
SMILES
  • [2H]C1([C@@H]2C[C@H](N1C(=O)C3=C(C(=CC=C3)F)C4=NC=CC=N4)[C@@H](C2)OC5=NC=C(C=C5)C(F)(F)F)[2H]
InChI
  • InChI=1S/C23H18F4N4O2/c24-16-4-1-3-15(20(16)21-28-7-2-8-29-21)22(32)31-12-13-9-17(31)18(10-13)33-19-6-5-14(11-30-19)23(25,26)27/h1-8,11,13,17-18H,9-10,12H2/t13-,17+,18-/m1/s1/i12D2
  • Key:HUKWIAXQBOHZIX-USKNZQBOSA-N

Tebideutorexant[2] (developmental code names JNJ-61393215, JNJ-3215) is an orexin antagonist medication which is under development for the treatment of depression and anxiety disorders.[3][4][5][6]

It is an orally active compound and acts as a selective antagonist of the orexin OX1 receptor (1-SORA).[4][5][6] Preliminary clinical findings suggest that tebideutorexant may have anti-panic effects in humans.[4][5] The elimination half-life of tebideutorexant is 13.6 to 24.6 hours.[1]

As of June 2023, tebideutorexant is in phase 2 clinical trials for the treatment of major depressive disorder while no further development has been reported for treatment of panic disorder and other anxiety disorders.[3] The drug was originated and developed by Janssen Pharmaceuticals.[3]

See also

References

  1. ^ a b Brooks S, Zuiker R, Bleys C, Ziagkos D, Moyer J, van Nueten L, et al. (2023). "Pharmacological characterization of the selective orexin-1 receptor antagonist JNJ-61393215 in healthy volunteers". Journal of Psychopharmacology. 37 (6): 577–589. doi:10.1177/02698811231167989. ISSN 0269-8811. PMID 37165642. Retrieved 27 July 2025.
  2. ^ PubChem. "Tebideutorexant". pubchem.ncbi.nlm.nih.gov. Retrieved 2024-08-15.
  3. ^ a b c "JNJ 61393215 - AdisInsight".
  4. ^ a b c Caldirola D, Alciati A, Cuniberti F, Perna G (2021). "Experimental Drugs for Panic Disorder: An Updated Systematic Review". Journal of Experimental Pharmacology. 13: 441–459. doi:10.2147/JEP.S261403. PMC 8055642. PMID 33889031.
  5. ^ a b c Jacobson LH, Hoyer D, de Lecea L (May 2022). "Hypocretins (orexins): The ultimate translational neuropeptides". Journal of Internal Medicine. 291 (5): 533–556. doi:10.1111/joim.13406. PMID 35043499. S2CID 248119793.
  6. ^ a b Salvadore G, Bonaventure P, Shekhar A, Johnson PL, Lord B, Shireman BT, et al. (September 2020). "Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans". Translational Psychiatry. 10 (1): 308. doi:10.1038/s41398-020-00937-9. PMC 7477545. PMID 32895369.



This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.